GlassScriptPhysician profile
Karen I Hunt
NPI 1891799524
$8,235.25
in general payments reported to CMS, 2019-2025
31 companies · $474 in 2025
The $474 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,983 · 2020: $1,462 · 2021: $1,761 · 2022: $1,181 · 2023: $830 · 2024: $543 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.91 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,098.80 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $1,009.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $593.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $542.20 | 2019-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $405.44 | 2019-2021 | |
| Lilly USA, LLC | $388.45 | 2019-2024 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.23 | 2019-2023 | Spiriva Respimat |
| Merck Sharp & Dohme LLC | $237.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $237.42 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $220.62 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $203.00 | 2022 | |
| Amgen INC. | $168.55 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $149.99 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.39 | 2019-2025 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $133.12 | 2020-2022 | |
| Gilead Sciences, INC. | $124.25 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.35 | 2019-2020 | |
| Hologic Sales and Service, LLC | $84.49 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $80.32 | 2019-2021 | |
| Eisai INC. | $78.27 | 2020-2021 | |
| Genentech USA, INC. | $68.68 | 2019 | |
| Allergan, INC. | $53.36 | 2019-2020 | |
| Inspire Medical Systems, INC. | $50.81 | 2025 | Inspire |
| Redhill Biopharma INC. | $40.21 | 2021 | |
| Esperion Therapeutics, INC. | $32.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.20 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.46 | 2021 | |
| Shield Therapeutics INC | $15.14 | 2023 | Accrufer |
| Viiv Healthcare Company | $13.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.